Recent News

• 03.05.2025 - Kamada Reports Record Top and Bottom Line 2024 Financial Results and Affirms 2025 Guidance Representing Double-Digit Profitable Growth
• 03.05.2025 - Kamada Declares Special Cash Dividend of $0.20 Per Share
• 02.26.2025 - Kamada to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 5, 2025
• 01.22.2025 - Kamada Announces a $25 Million 3-Year Contract for Supply of KAMRAB® and VARIZIG® in Latin America
• 01.08.2025 - Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025
• 11.13.2024 - Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability Guidance
• 11.06.2024 - Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024
• 11.06.2024 - Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024
• 11.04.2024 - Kamada to Present at the Stifel 2024 Healthcare Conference
• 11.04.2024 - Kamada to Present at the Stifel 2024 Healthcare Conference

Recent Filings

• 02.26.2025 - EX-99.1 EX-99.1
• 02.26.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.22.2025 - EX-99.1 EX-99.1
• 01.22.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 01.08.2025 - EX-99.1 EX-99.1
• 12.11.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.14.2024 - SC 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.13.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 11.06.2024 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]